Press Releases
La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
Nov 25, 2019
La Jolla Pharmaceutical Company Announces Management Transition
Nov 25, 2019
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress
Nov 12, 2019
La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Sep 05, 2019
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
Aug 29, 2019
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Progress
Aug 01, 2019
La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria
Jul 23, 2019
La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for the Treatment of Refractory Hypotension in Adults with Septic or Other Distributive Shock
Jun 28, 2019
La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
Jun 06, 2019
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
May 06, 2019
La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria
Apr 24, 2019
La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
Mar 11, 2019
La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
Mar 07, 2019
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives
Mar 04, 2019
La Jolla Pharmaceutical Company to Release Fourth Quarter and Full Year 2018 Financial Results on March 4, 2019
Feb 25, 2019
La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress
Feb 14, 2019
La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
Jan 07, 2019
La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
Jan 04, 2019